Literature DB >> 26708955

The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing.

Iris Schrijver1, Lynn Pique2, Steve Graham3, Michelle Pearl4, Athena Cherry5, Martin Kharrazi6.   

Abstract

Despite the implementation of cystic fibrosis (CF) newborn screening programs across the United States, the identification of CFTR gene variants in nonwhite populations compared with whites remains suboptimal. Our objective was to establish the spectrum of CFTR variants and their frequencies in CF patients in the United States with African, Native American, Asian, East Indian, or Middle Eastern backgrounds. By using direct DNA sequencing, we identified two CFTR variants in 89 of 140 affected nonwhite individuals with uncharacterized genotypes. Seven variants were novel. Multiplex ligation-dependent probe amplification detected 14 rearrangements in the remaining 51 patients, 6 of which were novel. Deletions and duplications accounted for 17% of unidentified alleles. A cross-sectional analysis of genotyping data from the CF Foundation Patient Registry was performed, comparing 3496 nonwhite patients with 22,206 white CF patients. Patients of Hispanic, black, or Asian ancestry were less likely to have two identified CFTR variants (P < 0.0001 for Hispanics and blacks, P = 0.003 for Asians), and more likely to carry no mutations on the commonly used 23 mutation carrier screening panel (P < 0.0001). We analyzed the mutations recorded for each ancestry and summarized the most frequent ones. This research could facilitate equity in mutation detection between white and nonwhite or mixed-ethnicity CF patients, enabling an earlier diagnosis improving their quality of life.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26708955     DOI: 10.1016/j.jmoldx.2015.07.005

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  29 in total

Review 1.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

2.  The Propagation of Race and Racial Differences as Biological in Preclinical Education.

Authors:  Zara Ibrahim; Claire Brown; Brendan Crow; Hailey Roumimper; Sarah Kureshi
Journal:  Med Sci Educ       Date:  2022-01-10

3.  Equitable Expanded Carrier Screening Needs Indigenous Clinical and Population Genomic Data.

Authors:  Simon Easteal; Ruth M Arkell; Renzo F Balboa; Shayne A Bellingham; Alex D Brown; Tom Calma; Matthew C Cook; Megan Davis; Hugh J S Dawkins; Marcel E Dinger; Michael S Dobbie; Ashley Farlow; Kylie G Gwynne; Azure Hermes; Wendy E Hoy; Misty R Jenkins; Simon H Jiang; Warren Kaplan; Stephen Leslie; Bastien Llamas; Graham J Mann; Brendan J McMorran; Rebekah E McWhirter; Cliff J Meldrum; Shivashankar H Nagaraj; Saul J Newman; Jack S Nunn; Lyndon Ormond-Parker; Neil J Orr; Devashi Paliwal; Hardip R Patel; Glenn Pearson; Greg R Pratt; Boe Rambaldini; Lynette W Russell; Ravi Savarirayan; Matthew Silcocks; John C Skinner; Yassine Souilmi; Carola G Vinuesa; Gareth Baynam
Journal:  Am J Hum Genet       Date:  2020-08-06       Impact factor: 11.025

4.  Whole exome and whole genome sequencing with dried blood spot DNA without whole genome amplification.

Authors:  Laia Bassaganyas; George Freedman; Dedeepya Vaka; Eunice Wan; Richard Lao; Flavia Chen; Mark Kvale; Robert J Currier; Jennifer M Puck; Pui-Yan Kwok
Journal:  Hum Mutat       Date:  2017-11-06       Impact factor: 4.878

5.  Next-Generation Molecular Testing of Newborn Dried Blood Spots for Cystic Fibrosis.

Authors:  Martina I Lefterova; Peidong Shen; Justin I Odegaard; Eula Fung; Tsoyu Chiang; Gang Peng; Ronald W Davis; Wenyi Wang; Martin Kharrazi; Iris Schrijver; Curt Scharfe
Journal:  J Mol Diagn       Date:  2016-02-01       Impact factor: 5.568

6.  Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico.

Authors:  Andrew M Zeiger; Meghan E McGarry; Angel C Y Mak; Vivian Medina; Sandra Salazar; Celeste Eng; Amy K Liu; Sam S Oh; Thomas J Nuckton; Deepti Jain; Thomas W Blackwell; Hyun Min Kang; Goncalo Abecasis; Leandra Cordero Oñate; Max A Seibold; Esteban G Burchard; Jose Rodriguez-Santana
Journal:  Pediatr Pulmonol       Date:  2019-10-30

Review 7.  The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Gianmarco Contino; Thomas L Vaughan; David Whiteman; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2017-07-14       Impact factor: 22.682

8.  Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?

Authors:  Robert J Currier; Stan Sciortino; Ruiling Liu; Tracey Bishop; Rasoul Alikhani Koupaei; Lisa Feuchtbaum
Journal:  Genet Med       Date:  2017-05-04       Impact factor: 8.822

9.  Genetic analysis and intracytoplasmic sperm injection outcomes of Chinese patients with congenital bilateral absence of vas deferens.

Authors:  Hongbo Cheng; Shenmin Yang; Qingxia Meng; Bo Zheng; Yidong Gu; Luyun Wang; Tao Song; Chunlu Xu; Gaigai Wang; Mutian Han; Liyan Shen; Jie Ding; Hong Li; Jun Ouyang
Journal:  J Assist Reprod Genet       Date:  2022-02-04       Impact factor: 3.412

10.  Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients.

Authors:  Lynn Pique; Steve Graham; Michelle Pearl; Martin Kharrazi; Iris Schrijver
Journal:  Genet Med       Date:  2016-05-05       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.